Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Orexigen Therapeutics submits MAA to EMA for Contrave

Oct. 4, 2013

DiaMedica reports phase I/II DM-199 data in type 2 diabetes

Oct. 4, 2013

DiaVacs commences phase Ib/IIa study of modified dendritic cells for type 1 diabetes

Oct. 4, 2013

Takeda Pharmaceutical synthesizes novel 5-HT2C receptor agonists

Oct. 3, 2013

Antihyperglycemia compound has novel molecular mechanism of action

Oct. 2, 2013

Study of LX-4211 in type 2 diabetes patients with renal impairment meets endpoint

Oct. 2, 2013

Researchers at Boehringer Ingelheim patent novel MCH-R1 antagonists

Oct. 2, 2013

Lithera reports data from the phase IIb RESET trial for LIPO-202

Oct. 1, 2013

Phase II clinical comparison of drug delivery systems in patients with type 2 diabetes

Oct. 1, 2013

Scientists create zebrafish model of hyperammonemia

Oct. 1, 2013

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...